Pharmacological treatment of increased vascular risk and cognitive performance in middle-aged and old persons: six-year observational longitudinal study
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Neurology
- Vol. 20 (1), 1-10
- https://doi.org/10.1186/s12883-020-01822-0
Abstract
Lowering vascular risk is associated with a decrease in the prevalence of cardiovascular disease and dementia. However, it is still unknown whether lowering of vascular risk with pharmacological treatment preserves cognitive performance in general. Therefore, we compared the change in cognitive performance in persons with and without treatment of vascular risk factors. In this longitudinal observational study, 256 persons (mean age, 58 years) were treated for increased vascular risk during a mean follow-up period of 5.5 years (treatment group), whereas 1678 persons (mean age, 50 years) did not receive treatment (control group). Cognitive performance was three times measured during follow-up using the Ruff Figural Fluency Test (RFFT) and Visual Association Test (VAT), and calculated as the average of standardized RFFT and VAT score per participant. Because treatment allocation was nonrandomized, additional analyses were performed in demographic and vascular risk-matched samples and adjusted for propensity scores. In the treatment group, mean (SD) cognitive performance changed from − 0.30 (0.80) to − 0.23 (0.80) to 0.02 (0.87), and in control group, from 0.08 (0.77) to 0.24 (0.79) to 0.49 (0.74) at the first, second and third measurement, respectively (ptrend < 0.001). After adjustment for demographics and vascular risk, the change in cognitive performance during follow-up was not statistically significantly different between the treatment and control group: mean estimated difference, − 0.10 (95%CI − 0.21 to 0.01; p = 0.08). Similar results were found in matched samples and after adjustment for propensity score. Change in cognitive performance during follow-up was similar in treated and untreated persons. This suggests that lowering vascular risk preserves cognitive performance.Funding Information
- Nierstichting (E033)
- Alzheimer Nederland (.)
This publication has 32 references indexed in Scilit:
- Scoring Higher the Second Time Around: Meta-Analyses of Practice Effects in Neuropsychological AssessmentThe Clinical Neuropsychologist, 2012
- Association of Cognitive Function with Albuminuria and eGFR in the General PopulationClinical Journal of the American Society of Nephrology, 2011
- Reference Data for the Ruff Figural Fluency Test Stratified by Age and Educational LevelPLOS ONE, 2011
- Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testingBMC Neuroscience, 2010
- Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic reviewVascular Health and Risk Management, 2010
- Albuminuria Assessed From First-Morning-Void Urine Samples Versus 24-Hour Urine Collections as a Predictor of Cardiovascular Morbidity and MortalityAmerican Journal of Epidemiology, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?Nephrology Dialysis Transplantation, 2003
- The ruff figural fluency test: A normative study with adultsDevelopmental Neuropsychology, 1987